research product . 2021

Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2

Corominas, Hèctor; Castellvi, Ivan; Díaz Torne, César; Matas, Laia; de la Rosa Carrillo, David; Mangues, Ma Antonia; Moya, Patricia; Pomar, Virginia; Benito, Natividad; Moga, Esther; ...
Open Access English
  • Published: 01 Jan 2021
  • Country: Spain
Abstract
Blocking IL-6 pathways with sarilumab, a fully human anti-IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.
Subjects
free text keywords: Covid-19, Critically ill, Sarilumab, SARS-Cov-2 infection
Related Organizations
Any information missing or wrong?Report an Issue